High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer's disease in human cerebrospinal fluid
RC Hendrickson, AYH Lee, Q Song, A Liaw, M Wiener… - PloS one, 2015 - journals.plos.org
Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in
medicine. Current trends suggest that biomarkers reflective of AD neuropathology and …
medicine. Current trends suggest that biomarkers reflective of AD neuropathology and …
Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics
KR Wildsmith, SP Schauer, AM Smith, D Arnott… - Molecular …, 2014 - Springer
Background Alzheimer's disease (AD) is the leading cause of dementia affecting greater
than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ 42, tau …
than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ 42, tau …
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease
RJ Perrin, R Craig-Schapiro, JP Malone, AR Shah… - PloS one, 2011 - journals.plos.org
Background Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied
during the 'preclinical'stage (pathology present with cognition intact) before severe neuronal …
during the 'preclinical'stage (pathology present with cognition intact) before severe neuronal …
A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …
pathophysiological changes that develop years before the onset of clinical symptoms. These …
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis
R Craig-Schapiro, M Kuhn, C Xiong, EH Pickering… - PloS one, 2011 - journals.plos.org
Background Clinicopathological studies suggest that Alzheimer's disease (AD) pathology
begins∼ 10–15 years before the resulting cognitive impairment draws medical attention …
begins∼ 10–15 years before the resulting cognitive impairment draws medical attention …
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's …
Alzheimer's disease (AD) is the most common cause of dementia. Biomarkers are required
to identify individuals in the preclinical phase, explain phenotypic diversity, measure …
to identify individuals in the preclinical phase, explain phenotypic diversity, measure …
Alzheimer's disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling
QQ Tao, X Cai, YY Xue, W Ge, L Yue, XY Li, RR Lin… - The Innovation, 2024 - cell.com
Amyloid-β, tau pathology, and biomarkers of neurodegeneration make up the core
diagnostic biomarkers of Alzheimer disease (AD). However, these proteins represent only a …
diagnostic biomarkers of Alzheimer disease (AD). However, these proteins represent only a …
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease
Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders
Biomarkers are needed to assist in the diagnosis and medical management of various
neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD) …
neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD) …
Alzheimer disease pathology and the cerebrospinal fluid proteome
Background Altered proteome profiles have been reported in both postmortem brain tissues
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …